LABCORP HOLDINGS INC. Pay versus Performance
The Pay versus Performance table from each proxy statement (Item 402(v)), as tagged in its XBRL, newest proxy first. Each proxy's own figures are kept, so a year restated in a later proxy appears once per proxy. PEO is the principal executive officer; NEO means the other named executive officers (average). Total shareholder return is the value of a $100 investment.
- 2025-12-31: PEO Adam H. Schechter; PEO total compensation $18.34M; PEO compensation actually paid $30.13M; Other NEO average total compensation $4.22M.
- 2024-12-31: PEO total compensation $19.33M; PEO compensation actually paid $21.33M; Other NEO average total compensation $3.72M.
- 2023-12-31: PEO total compensation $15.98M; PEO compensation actually paid $23.76M; Other NEO average total compensation $4.13M.
- 2022-12-31: PEO total compensation $14.93M; PEO compensation actually paid -$2.32M; Other NEO average total compensation $4.39M.
| Fiscal year end | PEO | PEO total compensation | PEO compensation actually paid | Other NEO average total compensation | Other NEO average compensation actually paid | Total shareholder return | Peer group total shareholder return | Net income | Company-selected measure | Proxy filed |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | Adam H. Schechter | $18.34M | $30.13M | $4.22M | $5.99M | $150.00 | $148.00 | $877.00M | Adjusted operating income $2.00B | 2026-04-10 |
| 2024-12-31 | $19.33M | $21.33M | $3.72M | $3.94M | $163.00 | $147.00 | $746.00M | $1.80B | 2026-04-10 | |
| 2023-12-31 | $15.98M | $23.76M | $4.13M | $4.76M | $160.00 | $143.00 | $418.00M | $1.19B | 2026-04-10 | |
| 2022-12-31 | $14.93M | -$2.32M | $4.39M | $788.13K | $140.00 | $140.00 | $1.28B | $2.55B | 2026-04-10 | |
| 2021-12-31 | $20.55M | $49.70M | $4.71M | $11.67M | $186.00 | $143.00 | $2.38B | $3.83B | 2026-04-10 | |
| 2024-12-31 | Adam Schechter | $19.33M | $21.33M | $3.72M | $3.94M | $163.00 | $147.00 | $746.00M | Adjusted operating income $1.80B | 2025-04-04 |
| 2023-12-31 | $15.98M | $23.76M | $4.13M | $4.76M | $160.00 | $143.00 | $418.00M | $1.19B | 2025-04-04 | |
| 2022-12-31 | $14.93M | -$2.32M | $4.39M | $788.13K | $140.00 | $140.00 | $1.28B | $2.55B | 2025-04-04 | |
| 2021-12-31 | $20.55M | $49.70M | $4.71M | $11.67M | $186.00 | $143.00 | $2.38B | $3.83B | 2025-04-04 | |
| 2020-12-31 | $14.74M | $18.90M | $3.40M | $4.64M | $120.00 | $113.00 | $1.56B | $3.33B | 2025-04-04 | |
| 2023-12-31 | Adam Schechter | $15.98M | $23.76M | $4.13M | $4.76M | $160.00 | $143.00 | $418.00M | Adjusted operating income $1.19B | 2024-04-04 |
| 2022-12-31 | $14.93M | -$2.32M | $4.39M | $788.13K | $140.00 | $140.00 | $1.28B | $2.55B | 2024-04-04 | |
| 2021-12-31 | $20.55M | $49.70M | $4.71M | $11.67M | $186.00 | $143.00 | $2.38B | $3.83B | 2024-04-04 | |
| 2020-12-31 | $14.74M | $18.90M | $3.40M | $4.64M | $120.00 | $113.00 | $1.56B | $3.33B | 2024-04-04 | |
| 2022-12-31 | Adam Schechter | $14.93M | -$2.32M | $4.39M | $788.13K | $140.00 | $140.00 | $1.28B | Adjusted operating income $2.55B | 2023-03-30 |
| 2021-12-31 | $20.55M | $49.70M | $4.71M | $11.67M | $186.00 | $143.00 | $2.38B | $3.83B | 2023-03-30 | |
| 2020-12-31 | $14.74M | $18.90M | $3.40M | $4.64M | $120.00 | $113.00 | $1.56B | $3.33B | 2023-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| QUEST DIAGNOSTICS INC (DGX) | United States | $26.096B | 22.09 |
| Guardant Health, Inc. (GH) | United States | $23.675B | -12.65 |
| Caris Life Sciences, Inc. (CAI) | United States | $9.119B | 47.87 |
| RadNet, Inc. (RDNT) | United States | $5.611B | -229.65 |
| GRAIL, Inc. (GRAL) | United States | $5.591B | -7.78 |
| VERACYTE, INC. (VCYT) | United States | $3.904B | 41.21 |
| Celcuity Inc. (CELC) | United States | $3.887B | -22.62 |
| CareDx, Inc. (CDNA) | United States | $3.174B | 13.21 |
| Fortrea Holdings Inc. (FTRE) | United States | $1.903B | -19.43 |
| Personalis, Inc. (PSNL) | United States | $1.769B | -13.30 |